Preview
Sign-in for full Details 
Sign-in free and Explore the Exciting World of BiomedExperts:
- Over 1.500.000 Profiles
- More than 1.800 Organizations worldwide
- State of the Art Network Visualizations
- Manage your own Profile
- Locate Experts in your Country/Region
- Locate Experts in your 1. and 2. Level Network
- Connect to Experts Worldwide
NetworkView
Joan Bladé
This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers
together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles
free of charge to researchers worldwide.
Research Profile (preview)
Disorders
Chemicals & Drugs
Procedures
Concepts & Ideas
Phenomena
Physiology
Sign-in to see full Profile
Network (preview)
35
Rosiñol, Laura
34
Montserrat, Emili
20
Rozman, Ciril
19
San Miguel, Jesús
16
Esteve, Jordi
15
Cibeira, Teresa
14
Cervantes, Francisco
14
Sureda, Anna
13
Montoto, Silvia
12
Lahuerta, Juan José
12
de la Rubia, Javier
10
Alegre, Adrián
10
García-Laraña, José
9
Mateo, Gema
9
San Miguel, Jesús
Sign-in to see all Coauthors
Publications
Sign-in to see all Publications
Sign in free and see...
Visualized networks:
See your personal network in
sophisticated graphical views
GeoTargeted Searches:
Locate experts around the world
and connect with global collaborators
Research Profiles:
See the visualized research activity
of experts around the globe
Sign-in to see more
Geonetwork of Joan Bladé (preview)
Cities where this author has publications
Cities where co-authors of this author have publications
Sign-in to see more
All Publications
-
2009: Paiva Bruno; Vidriales Maria-Belén; Pérez Jose J; Mateo Gema; Montalbán Maria Angeles; Mateos Maria Victoria; Bladé Joan; Lahuerta Juan José; Orfao Alberto; San Miguel Jesús F;
Multiparameter flow cytometry quantification of bone marrow plasma cells at diagnosis provides more prognostic information than morphological assessment in myeloma patients.
Haematologica 2009;94(11):1599-602.
-
2009: Bladé Joan; Rosiñol Laura; Cibeira Ma Teresa
Are all myelomas preceded by MGUS?
Blood 2009;113(22):5370.
-
2009: Richardson Paul G; Sonneveld Pieter; Schuster Michael W; Stadtmauer Edward A; Facon Thierry; Harousseau Jean-Luc; Ben-Yehuda Dina; Lonial Sagar; Goldschmidt Hartmut; Reece Donna; Bladé Joan; Boccadoro Mario; Cavenagh Jamie D; Boral Anthony L; Esseltine Dixie-Lee; Wen Patrick Y; Amato Anthony A; Anderson Kenneth C; San Miguel Jesus
Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline.
British journal of haematology 2009;144(6):895-903.
-
2009: Bladé Joan; Rosiñol Laura
Changing paradigms in the treatment of multiple myeloma.
Haematologica 2009;94(2):163-6.
-
2009: Fernández de Larrea Carlos; Rovira Montserrat; Mascaró José M; Torras Albert; Solé Manel; Lloreta Josep; Serra Núria; Cibeira Maria Teresa; Bladé Joan
Generalized cutis laxa and fibrillar glomerulopathy resulting from IgG Deposition in IgG-lambda Monoclonal Gammopathy: pulmonary hemorrhage during stem cell mobilization and complete hematological response with bortezomib and dexamethasone therapy.
European journal of haematology 2009;82(2):154-8.
-
2008: Bladé Joan; Sonneveld Pieter; San Miguel Jesús F; Sutherland Heather J; Hajek Roman; Nagler Arnon; Spencer Andrew; Robak Tadeusz; Cibeira M Teresa; Zhuang Sen H; Harousseau Jean-Luc; Orlowski Robert Z;
Pegylated liposomal doxorubicin plus bortezomib in relapsed or refractory multiple myeloma: efficacy and safety in patients with renal function impairment.
Clinical lymphoma & myeloma 2008;8(6):352-5.
-
2008: Lahuerta Juan José; Mateos Maria Victoria; Martínez-López Joaquin; Rosiñol Laura; Sureda Anna; de la Rubia Javier; García-Laraña José; Martínez-Martínez Rafael; Hernández-García Miguel T; Carrera Dolores; Besalduch Joan; de Arriba Felipe; Ribera José María; Escoda Lourdes; Hernández-Ruiz Belén; García-Frade Javier; Rivas-González Concepción; Alegre Adrían; Bladé Joan; San Miguel Jesús F
Influence of pre- and post-transplantation responses on outcome of patients with multiple myeloma: sequential improvement of response and achievement of complete response are associated with longer survival.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(35):5775-82.
-
2008: Bladé Joan; Rosiñol Laura
Advances in therapy of multiple myeloma.
Current opinion in oncology 2008;20(6):697-704.
-
2008: Paiva Bruno; Vidriales Maria-Belén; Cerveró Jorge; Mateo Gema; Pérez Jose J; Montalbán Maria A; Sureda Anna; Montejano Laura; Gutiérrez Norma C; García de Coca Alfonso; de Las Heras Natalia; Mateos Maria V; López-Berges Maria C; García-Boyero Raimundo; Galende Josefina; Hernández Jose; Palomera Luis; Carrera Dolores; Martínez Rafael; de la Rubia Javier; Martín Alejandro; Bladé Joan; Lahuerta Juan J; Orfao Alberto; San Miguel Jesús F;
Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation.
Blood 2008;112(10):4017-23.
-
2008: Rosiñol Laura; Pérez-Simón José Antonio; Sureda Anna; de la Rubia Javier; de Arriba Felipe; Lahuerta Juan José; González José David; Díaz-Mediavilla Joaquín; Hernández Belén; García-Frade Javier; Carrera Dolores; León Angel; Hernández Miguel; Abellán Pascual Fernández; Bergua Juan Miguel; San Miguel Jesús; Bladé Joan;
A prospective PETHEMA study of tandem autologous transplantation versus autograft followed by reduced-intensity conditioning allogeneic transplantation in newly diagnosed multiple myeloma.
Blood 2008;112(9):3591-3.
-
2008: de Larrea Carlos Fernández; Cibeira Maria Teresa; Vallansot Rolando; Colomo Lluís; Bladé Joan
Increased serum tumor markers (CA125 and CA15.3) in primary plasma cell leukemia: a case report and review of the literature.
Clinical lymphoma & myeloma 2008;8(5):312-4.
-
2008: Lonial Sagar; Richardson Paul G; San Miguel Jesús; Sonneveld Pieter; Schuster Michael W; Bladé Joan; Cavenagh Jamie; Rajkumar S Vincent; Jakubowiak Andrzej J; Esseltine Dixie-Lee; Anderson Kenneth C; Harousseau Jean-Luc
Characterisation of haematological profiles and low risk of thromboembolic events with bortezomib in patients with relapsed multiple myeloma.
British journal of haematology 2008;143(2):222-9.
-
2008: Bladé J; Rosiñol L; Cibeira M T
Prognostic factors for multiple myeloma in the era of novel agents.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2008;19 Suppl 7():vii117-20.
-
2008: Niesvizky Ruben; Richardson Paul G; Rajkumar S Vincent; Coleman Morton; Rosiñol Laura; Sonneveld Pieter; Schuster Michael W; Irwin David; Stadtmauer Edward A; Facon Thierry; Harousseau Jean-Luc; Boral Anthony L; Esseltine Dixie-Lee; Anderson Kenneth C; Bladé Joan
The relationship between quality of response and clinical benefit for patients treated on the bortezomib arm of the international, randomized, phase 3 APEX trial in relapsed multiple myeloma.
British journal of haematology 2008;143(1):46-53.
-
2008: Mateo Gema; Montalbán M Angeles; Vidriales Maria-Belén; Lahuerta Juan J; Mateos Maria V; Gutiérrez Norma; Rosiñol Laura; Montejano Laura; Bladé Joan; Martínez Rafael; de la Rubia Javier; Diaz-Mediavilla Joaquín; Sureda Anna; Ribera José M; Ojanguren José M; de Arriba Felipe; Palomera Luis; Terol Maria J; Orfao Alberto; San Miguel Jesús F;
Prognostic value of immunophenotyping in multiple myeloma: a study by the PETHEMA/GEM cooperative study groups on patients uniformly treated with high-dose therapy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(16):2737-44.
-
2008: Rajkumar S Vincent; Rosiñol Laura; Hussein Mohamad; Catalano John; Jedrzejczak Wieslaw; Lucy Lela; Olesnyckyj Marta; Yu Zhinuan; Knight Robert; Zeldis Jerome B; Bladé Joan
Multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(13):2171-7.
-
2008: Mateos María-Victoria; Hernández José M; Hernández Miguel T; Gutiérrez Norma C; Palomera Luis; Fuertes Marta; Garcia-Sanchez Pedro; Lahuerta Juán J; de la Rubia Javier; Terol María-José; Sureda Ana; Bargay Joan; Ribas Paz; Alegre Adrian; de Arriba Felipe; Oriol Albert; Carrera Dolores; García-Laraña José; García-Sanz Ramón; Bladé Joan; Prósper Felipe; Mateo Gemma; Esseltine Dixie-Lee; van de Velde Helgi; San Miguel Jesús F
Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: updated time-to-events results and prognostic factors for time to progression.
Haematologica 2008;93(4):560-5.
-
2008: Sonneveld Pieter; Hajek Roman; Nagler Arnon; Spencer Andrew; Bladé Joan; Robak Tadeusz; Zhuang Sen H; Harousseau Jean-Luc; Orlowski Robert Z;
Combined pegylated liposomal doxorubicin and bortezomib is highly effective in patients with recurrent or refractory multiple myeloma who received prior thalidomide/lenalidomide therapy.
Cancer 2008;112(7):1529-37.
-
2008: San-Miguel J F; Richardson P G; Sonneveld P; Schuster M W; Irwin D; Stadtmauer E A; Facon T; Harousseau J-L; Ben-Yehuda D; Lonial S; Goldschmidt H; Reece D; Bladé J; Boccadoro M; Cavenagh J D; Neuwirth R; Boral A L; Esseltine D-L; Anderson K C
Efficacy and safety of bortezomib in patients with renal impairment: results from the APEX phase 3 study.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2008;22(4):842-9.
-
2008: Richardson Paul G; Niesvizky Ruben; Anderson Kenneth C; Bladé Joan
Re: When you look matters: the effect of assessment schedule on progression-free survival.
Journal of the National Cancer Institute 2008;100(5):373.
-
2008: Cibeira M Teresa; Rozman María; Segarra Marta; Lozano Esther; Rosiñol Laura; Cid Maria C; Filella Xavier; Bladé Joan
Bone marrow angiogenesis and angiogenic factors in multiple myeloma treated with novel agents.
Cytokine 2008;41(3):244-53.
-
2008: Fernández de Larrea Carlos; Cibeira Maria Teresa; Rovira Montserrat; Rosiñol Laura; Esteve Jordi; Bladé Joan
Spontaneous rupture of the spleen as immediate complication in autologous transplantation for primary systemic amyloidosis.
European journal of haematology 2008;80(2):182-4.
-
2007: Carreras Enric; Rosiñol Laura; Terol Maria José; Alegre Adrián; de Arriba Felipe; García-Laraña José; Bello José Luis; García Raimundo; León Angel; Martínez Rafael; Peñarrubia M Jesús; Poderós Concha; Ribas Paz; Ribera Josep Maria; San Miguel Jesús; Bladé Joan; Lahuerta Juan José;
Veno-occlusive disease of the liver after high-dose cytoreductive therapy with busulfan and melphalan for autologous blood stem cell transplantation in multiple myeloma patients.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2007;13(12):1448-54.
-
2007: Bladé Joan; Rosiñol Laura
Complications of multiple myeloma.
Hematology/oncology clinics of North America 2007;21(6):1231-46, xi.
-
2007: Richardson Paul G; Sonneveld Pieter; Schuster Michael; Irwin David; Stadtmauer Edward; Facon Thierry; Harousseau Jean-Luc; Ben-Yehuda Dina; Lonial Sagar; Goldschmidt Hartmut; Reece Donna; Miguel Jesus San; Bladé Joan; Boccadoro Mario; Cavenagh Jamie; Alsina Melissa; Rajkumar S Vincent; Lacy Martha; Jakubowiak Andrzej; Dalton William; Boral Anthony; Esseltine Dixie-Lee; Schenkein David; Anderson Kenneth C
Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial.
Blood 2007;110(10):3557-60.
-
2007: Abrisqueta Pau; Rovira Montserrat; Cibeira María Teresa; Vallansot Rolando; Gutiérrez Gonzalo; Bladé Joan; Carreras Enric; Montserrat Emili
[Autologous haematopoietic stem cell transplantation in POEMS syndrome: results in 4 cases]
Medicina clínica 2007;129(15):578-81.
-
2007: Rosiñol Laura; Oriol Albert; Mateos Maria Victoria; Sureda Anna; García-Sánchez Pedro; Gutiérrez Norma; Alegre Adrián; Lahuerta Juan José; de la Rubia Javier; Herrero Carlos; Liu Xiangyang; Van de Velde Helgi; San Miguel Jesús; Bladé Joan
Phase II PETHEMA trial of alternating bortezomib and dexamethasone as induction regimen before autologous stem-cell transplantation in younger patients with multiple myeloma: efficacy and clinical implications of tumor response kinetics.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(28):4452-8.
-
2007: Orlowski Robert Z; Nagler Arnon; Sonneveld Pieter; Bladé Joan; Hajek Roman; Spencer Andrew; San Miguel Jesús; Robak Tadeusz; Dmoszynska Anna; Horvath Noemi; Spicka Ivan; Sutherland Heather J; Suvorov Alexander N; Zhuang Sen H; Parekh Trilok; Xiu Liang; Yuan Zhilong; Rackoff Wayne; Harousseau Jean-Luc
Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(25):3892-901.
-
2007: Rosiñol Laura; Cibeira M Teresa; Montoto Silvia; Rozman María; Esteve Jordi; Filella Xavier; Bladé Joan
Monoclonal gammopathy of undetermined significance: predictors of malignant transformation and recognition of an evolving type characterized by a progressive increase in M protein size.
Mayo Clinic proceedings. Mayo Clinic 2007;82(4):428-34.
-
2006: Bladé Joan
Clinical practice. Monoclonal gammopathy of undetermined significance.
The New England journal of medicine 2006;355(26):2765-70.
-
2006: Cibeira M Teresa; Rosiñol Laura; Ramiro Laia; Esteve Jordi; Torrebadell Montserrat; Bladé Joan
Long-term results of thalidomide in refractory and relapsed multiple myeloma with emphasis on response duration.
European journal of haematology 2006;77(6):486-92.
-
2006: Mateos María-Victoria; Hernández José-M; Hernández Miguel-T; Gutiérrez Norma-C; Palomera Luis; Fuertes Marta; Díaz-Mediavilla Joaquín; Lahuerta Juan-J; de la Rubia Javier; Terol María-José; Sureda Ana; Bargay Joan; Ribas Paz; de Arriba Felipe; Alegre Adrian; Oriol Albert; Carrera Dolores; García-Laraña José; García-Sanz Ramón; Bladé Joan; Prósper Felipe; Mateo Gemma; Esseltine Dixie-Lee; van de Velde Helgi; San Miguel Jesús-F
Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study.
Blood 2006;108(7):2165-72.
-
2006: Bladé Joan
Autologous transplantation in multiple myeloma.
Haematologica 2006;91(9):1157.
-
2006: San-Miguel Jesús; Bladé Joan
Perspective on the current use of bortezomib in multiple myeloma.
Haematologica 2006;91(7):871-2.
-
2006: de la Rubia Javier; Bladé Joan; Lahuerta Juan-José; Ribera Josep M; Martínez Rafael; Alegre Adrián; García-Laraña José; Fernández Pascual; Sureda Anna; de Arriba Felipe; Carrera Dolores; Besalduch Joan; García Boyero Raimundo; Palomera Bernal Luis; Hernández Miguel T; García Paz Ribas; Pérez-Calvo Javier; Alcalá Antonio; Casado Luis Felipe; San Miguel Jesús
Effect of chemotherapy with alkylating agents on the yield of CD34+ cells in patients with multiple myeloma. Results of the Spanish Myeloma Group (GEM) Study.
Haematologica 2006;91(5):621-7.
-
2006: Bladé Joan; Rosiñol Laura
Smoldering multiple myeloma and monoclonal gammopathy of undetermined significance.
Current treatment options in oncology 2006;7(3):237-45.
-
2006: Laura Rosiñol; Cibeira Maria Teresa; Uriburu Carla; Yantorno Sebastián; Salamero Olga; Bladé Joan; Montserrat Emili
Bortezomib: an effective agent in extramedullary disease in multiple myeloma.
European journal of haematology 2006;76(5):405-8.
-
2006: Kimby Eva; Treon Steven P; Anagnostopoulos Athanasios; Dimopoulos Meletios; Garcia-Sanz Ramon; Gertz Morie A; Johnson Stephen; LeBlond Veronique; Fermand Jean-Paul; Maloney David G; Merlini Giampaolo; Morel Pierre; Morra Enrica; Nichols Gwen; Ocio Enrique M; Owen Roger; Stone Marvin; Bladé Joan
Update on recommendations for assessing response from the Third International Workshop on Waldenstrom's Macroglobulinemia.
Clinical lymphoma & myeloma 2006;6(5):380-3.
-
2006: San Miguel Jesús; Bladé Joan; Boccadoro Mario; Cavenagh Jamie; Glasmacher Axel; Jagannath Sundar; Lonial Sagar; Orlowski Robert Z; Sonneveld Pieter; Ludwig Heinz
A practical update on the use of bortezomib in the management of multiple myeloma.
The oncologist 2006;11(1):51-61.
-
2006: Samanez César; Domingo Abel; Cibeira M Teresa; Miquel Rosa; Soler Manel; Bladé Joan
Development of rapidly progressive liver light chain deposition under VAD chemotherapy in multiple myeloma.
European journal of haematology 2006;76(1):83-5.
-
2006: Cibeira M Teresa; Mercadal Santiago; Arenillas Leonor; Muntañola Anna; Salamero Olga; Bladé Joan
Bortezomib-induced rhabdomyolysis in multiple myeloma.
Acta haematologica 2006;116(3):203-6.
-
2005: Bladé Joan; Rosiñol Laura; Sureda Ana; Ribera Josep M; Díaz-Mediavilla Joaquín; García-Laraña José; Mateos M Victoria; Palomera Luis; Fernández-Calvo Javier; Martí Josep M; Giraldo Pilar; Carbonell Félix; Callís Manel; Trujillo Jesús; Gardella Santiago; Moro M Jesús; Barez Abelardo; Soler Alfons; Font Llorenç; Fontanillas Montserrat; San Miguel Jesús;
High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA.
Blood 2005;106(12):3755-9.
-
2005: Rosiñol Laura; Carrió Ana; Bladé Joan; Queralt Rosa; Aymerich Marta; Cibeira Ma Teresa; Esteve Jordi; Rozman Maria; Campo Elías; Montserrat Emili
Comparative genomic hybridisation identifies two variants of smoldering multiple myeloma.
British journal of haematology 2005;130(5):729-32.
-
2005: Richardson Paul G; Sonneveld Pieter; Schuster Michael W; Irwin David; Stadtmauer Edward A; Facon Thierry; Harousseau Jean-Luc; Ben-Yehuda Dina; Lonial Sagar; Goldschmidt Hartmut; Reece Donna; San-Miguel Jesus F; Bladé Joan; Boccadoro Mario; Cavenagh Jamie; Dalton William S; Boral Anthony L; Esseltine Dixie L; Porter Jane B; Schenkein David; Anderson Kenneth C;
Bortezomib or high-dose dexamethasone for relapsed multiple myeloma.
The New England journal of medicine 2005;352(24):2487-98.
-
2005: Mateo Gema; Castellanos Mariana; Rasillo Ana; Gutiérrez Norma C; Montalbán Ma Angeles; Martín Ma Luisa; Hernández Jesús Ma; López-Berges Ma Consuelo; Montejano Laura; Bladé Joan; Mateos Ma Victoria; Sureda Anna; de la Rubia Javier; Díaz-Mediavilla Joaquín; Pandiella Atanasio; Lahuerta Juan José; Orfao Alberto; San Miguel Jesús F
Genetic abnormalities and patterns of antigenic expression in multiple myeloma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(10):3661-7.
-
2005: Greipp Philip R; San Miguel Jesus; Durie Brian G M; Crowley John J; Barlogie Bart; Bladé Joan; Boccadoro Mario; Child J Anthony; Avet-Loiseau Herve; Kyle Robert A; Lahuerta Juan J; Ludwig Heinz; Morgan Gareth; Powles Raymond; Shimizu Kazuyuki; Shustik Chaim; Sonneveld Pieter; Tosi Patrizia; Turesson Ingemar; Westin Jan
International staging system for multiple myeloma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(15):3412-20.
-
2005: Esparís-Ogando Azucena; Alegre Adrián; Aguado Beatriz; Mateo Gema; Gutiérrez Norma; Bladé Joan; Schenkein David; Pandiella Atanasio; San Miguel Jesús F
Bortezomib is an efficient agent in plasma cell leukemias.
International journal of cancer. Journal international du cancer 2005;114(4):665-7.
-
2005: Rosiñol Laura; Montoto Silvia; Cibeira Maria Teresa; Bladé Joan
Bortezomib-induced severe hepatitis in multiple myeloma: a case report.
Archives of internal medicine 2005;165(4):464-5.
-
2005: Bladé Joan; Cibeira M Teresa; Rosiñol Laura
Bortezomib: a valuable new antineoplastic strategy in multiple myeloma.
Acta oncologica (Stockholm, Sweden) 2005;44(5):440-8.
-
2005: Bladé Joan; Rosiñol Laura
Renal, hematologic and infectious complications in multiple myeloma.
Best practice & research. Clinical haematology 2005;18(4):635-52.
-
2004: Hernández J M; García-Sanz R; Golvano E; Bladé J; Fernandez-Calvo J; Trujillo J; Soler J A; Gardella S; Carbonell F; Mateo G; San Miguel J F
Randomized comparison of dexamethasone combined with melphalan versus melphalan with prednisone in the treatment of elderly patients with multiple myeloma.
British journal of haematology 2004;127(2):159-64.
-
2004: Montoto S; López-Guillermo A; Altés A; Perea G; Ferrer A; Camós M; Villela L; Bosch F; Esteve J; Cervantes F; Bladé J; Nomdedeu B; Campo E; Sierra J; Montserrat E
Predictive value of Follicular Lymphoma International Prognostic Index (FLIPI) in patients with follicular lymphoma at first progression.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2004;15(10):1484-9.
-
2004: Montagut Clara; Bosch Francesc; Villela Luís; Rosiñol Laura; Bladé Joan
Aminoglycoside-associated severe renal failure in patients with multiple myeloma treated with thalidomide.
Leukemia & lymphoma 2004;45(8):1711-2.
-
2004: Rosiñol Laura; Cibeira Ma Teresa; Bladé Joan; Esteve Jordi; Aymerich Marta; Rozman María; Segarra Marta; Cid Maria C; Filella Xavier; Montserrat Emili
Extramedullary multiple myeloma escapes the effect of thalidomide.
Haematologica 2004;89(7):832-6.
-
2004: Bladé Joan
On the "significance" of monoclonal gammopathy of undetermined significance.
Mayo Clinic proceedings. Mayo Clinic 2004;79(7):855-6.
-
2004: Rosiñol Laura; Cibeira M Teresa; Segarra Marta; Cid Maria C; Filella Xavier; Aymerich Marta; Rozman María; Arenillas Leonor; Esteve Jordi; Bladé Joan; Montserrat Emili
Response to thalidomide in multiple myeloma: impact of angiogenic factors.
Cytokine 2004;26(4):145-8.
-
2004: Bladé Joan; Rosiñol Laura
Moving forward in myeloma research.
Haematologica 2004;89(5):517-9.
-
2004: Nadal E; Giné E; Bladé J; Esteve J; Rosiñol L; Fernández-Avilés F; Marin P; Martinez C; Rovira M; Urbano-Ispizua A; Carreras E; Montserrat E
High-dose therapy/autologous stem cell transplantation in patients with chemosensitive multiple myeloma: predictors of complete remission.
Bone marrow transplantation 2004;33(1):61-4.
-
2003: Rosiñol L; Bladé J; Esteve J; Aymerich M; Rozman M; Montoto S; Giné E; Nadal E; Filella X; Queralt R; Carrió A; Montserrat E
Smoldering multiple myeloma: natural history and recognition of an evolving type.
British journal of haematology 2003;123(4):631-6.
-
2003: Bladé Joan; Vesole David H; Gertz Morie
High-dose therapy in multiple myeloma.
Blood 2003;102(10):3469-70.
-
2003: Arrizabalaga P; Saurina A; Solé M; Bladé J
Henoch-Schönlein IgA glomerulonephritis complicating myeloma kidneys: case report.
Annals of hematology 2003;82(8):526-8.
-
2003: Bladé Joan; Montoto Silvia; Rosiñol Laura; Montserrat Emili
Appropriateness of applying the response criteria for multiple myeloma to Waldenstrom's macroglobulinemia?
Seminars in oncology 2003;30(2):329-31.
-
2003: Montoto S; Rozman M; Rosiñol L; Nadal E; Giné E; Aymerich M; Ferrer A; Esteve J; Bosch F; López-Guillermo A; Bladé J; Montserrat E
Malignant transformation in IgM monoclonal gammopathy of undetermined significance.
Seminars in oncology 2003;30(2):178-81.
-
2003: Weber Donna; Treon Steven P; Emmanouilides Christos; Branagan Andrew R; Byrd John C; Bladé Joan; Kimby Eva
Uniform response criteria in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia.
Seminars in oncology 2003;30(2):127-31.
-
2003: Bladé Joan; Rosiñol Laura
Thalidomide: a step forward in the treatment of malignant monoclonal gammopathies.
Clinical lymphoma 2003;3(4):247-8.
-
2002: Rives S; Pera M; Rosiñol L; Vidal O; Miquel R; Solé M; García-Valdecasas J; Bladé J
Primary systemic amyloidosis presenting as a colonic stricture: successful treatment with left hemicolectomy followed by autologous hematopoietic stem-cell transplantation: report of a case.
Diseases of the colon and rectum 2002;45(9):1263-6.
-
2002: Martín Alejandro; García-Sanz Ramón; Hernández José; Bladé Joan; Suquía Begoña; Fernández-Calvo Javier; González Marcos; Mateo Gema; Orfao Alberto; San Miguel Jesus F
Pamidronate induces bone formation in patients with smouldering or indolent myeloma, with no significant anti-tumour effect.
British journal of haematology 2002;118(1):239-42.
-
2002: Montoto Silvia; Bladé Joan; Montserrat Emili
Monoclonal gammopathy of undetermined significance.
The New England journal of medicine 2002;346(26):2087-8; author reply 2087-8.
-
2002: Alegre Adrián; Granda Asunción; Martínez-Chamorro Carmen; Díaz-Mediavilla Joaquín; Martínez Rafael; García-Laraña José; Lahuerta Juan-José; Sureda Anna; Bladé Joan; de la Rubia Javier; Fernández-Rañada José Maria; San Miguel Jesús;
Different patterns of relapse after autologous peripheral blood stem cell transplantation in multiple myeloma: clinical results of 280 cases from the Spanish Registry.
Haematologica 2002;87(6):609-14.
-
2002: Bladé Joan; Filella Xabier; Montoto Silvia; Bosch Francesc; Rosiñol Laura; Coca Francesca; Giné Eva; Nadal Elisabeth; Aymerich Marta; Rozman María; Montserrat Emili
Interleukin 6 and tumour necrosis factor alpha serum levels in monoclonal gammopathy of undetermined significance.
British journal of haematology 2002;117(2):387-9.
-
2002: Montoto S; López-Guillermo A; Ferrer A; Camós M; Alvarez-Larrán A; Bosch F; Bladé J; Cervantes F; Esteve J; Cobo F; Colomer D; Campo E; Montserrat E
Survival after progression in patients with follicular lymphoma: analysis of prognostic factors.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2002;13(4):523-30.
-
2002: San Miguel Jesús F; Almeida Julia; Mateo Gema; Bladé Joan; López-Berges Consuelo; Caballero Dolores; Hernández José; Moro María Jesús; Fernández-Calvo Javier; Díaz-Mediavilla Joaquín; Palomera Luis; Orfao Alberto
Immunophenotypic evaluation of the plasma cell compartment in multiple myeloma: a tool for comparing the efficacy of different treatment strategies and predicting outcome.
Blood 2002;99(5):1853-6.
-
2002: Jiménez-Hernández M; López-Guillermo A; Cobo F; Bladé J; Aguilar J L; Villamor N; Montserrat E
Bladder involvement of diffuse large B-cell lymphoma diagnosed by a cytological study of the urine.
Leukemia & lymphoma 2002;43(1):187-9.
-
2001: Bladé J; Esteve J; Rosiñol L; Perales M; Montoto S; Tuset M; Montserrat E
Thalidomide in refractory and relapsing multiple myeloma.
Seminars in oncology 2001;28(6):588-92.
-
2001: Bladé J; Perales M; Rosiñol L; Tuset M; Montoto S; Esteve J; Cobo F; Villela L; Rafel M; Nomdedeu B; Montserrat E
Thalidomide in multiple myeloma: lack of response of soft-tissue plasmacytomas.
British journal of haematology 2001;113(2):422-4.
-
2001: Bladé J; San Miguel J F; Fontanillas M; Esteve J; Maldonado J; Alcalá A; Brunet S; García-Conde J; Besalduch J; Moro M J; Fernández-Calvo J; Conde E; Font L; Gardella S; Carnero M; Carbonell F; Martí J M; Hernández-Martín J; Ortega F; Besses C; Ribera J M; Trujillo J; Escudero M L; Rozman C; Estapé J; Montserrat E
Increased conventional chemotherapy does not improve survival in multiple myeloma: long-term results of two PETHEMA trials including 914 patients.
The hematology journal : the official journal of the European Haematology Association / EHA 2001;2(4):272-8.
-
2000: Bladé J; Esteve J; Rives S; Martínez C; Rovira M; Urbano-Ispizua A; Marín P; Carreras E; Montserrat E
High-dose therapy autotransplantation/intensification vs continued standard chemotherapy in multiple myeloma in first remission. Results of a non-randomized study from a single institution.
Bone marrow transplantation 2000;26(8):845-9.
-
2000: Gómez E; Roncero C; De Pablo J; Rovira M; Mazzarra R; Bladé J; Cirera E
[Hyperviscosity syndrome and mental disorders]
Actas españolas de psiquiatría 2000;28(4):263-6.
-
2000: Rives S; Bladé J; Martínez C; Marín P; Carreras E; Montserrat E
[High-dose melphalan treatment followed by hematopoietic progenitor cell rescue in primary amyloidosis]
Medicina clínica 2000;115(6):216-20.
-
2000: Lahuerta J J; Martinez-Lopez J; Serna J D; Bladé J; Grande C; Alegre A; Vazquez L; García-Laraña J; Sureda A; Rubia J D; Conde E; Martinez R; Perez-Equiza K; Moraleda J M; León A; Besalduch J; Cabrera R; Miguel J D; Morales A; García-Ruíz J C; Diaz-Mediavilla J; San-Miguel J
Remission status defined by immunofixation vs. electrophoresis after autologous transplantation has a major impact on the outcome of multiple myeloma patients.
British journal of haematology 2000;109(2):438-46.
-
2000: Lahuerta J J; Martinez-Lopez J; Grande C; Bladé J; de la Serna J; Alegre A; García-Laraña J; Caballero D; Sureda A; de la Rubia J; Alvarez A M; Marín J; Escudero A; Conde E; Perez-Equiza K; García Ruiz J C; Moraleda J M; León A; Bargay J; Cabrera R; Hernandez-García M T; Diaz-Mediavilla J; Miguel J S
Conditioning regimens in autologous stem cell transplantation for multiple myeloma: a comparative study of efficacy and toxicity from the Spanish Registry for Transplantation in Multiple Myeloma.
British journal of haematology 2000;109(1):138-47.
-
1999: Bladé J; Kyle R A
Nonsecretory myeloma, immunoglobulin D myeloma, and plasma cell leukemia.
Hematology/oncology clinics of North America 1999;13(6):1259-72.
-
1999: Gómez E; Roncero C; de Pablo J; Bladé J
[Acute confusion syndrome secondary to hyperviscosity in multiple myeloma]
Medicina clínica 1999;113(16):635.
-
1999: Bladé J
Therapeutic strategies and controversies in the treatment of multiple myeloma.
Pathologie-biologie 1999;47(2):192-8.
-
1999: García-Sanz R; Orfão A; González M; Tabernero M D; Bladé J; Moro M J; Fernández-Calvo J; Sanz M A; Pérez-Simón J A; Rasillo A; Miguel J F
Primary plasma cell leukemia: clinical, immunophenotypic, DNA ploidy, and cytogenetic characteristics.
Blood 1999;93(3):1032-7.
-
1998: Filella X; Bladé J; Montoto S; Molina R; Coca F; Montserrat E; Ballesta A M
Impaired production of interleukin 6 and tumour necrosis factor alpha in whole blood cell cultures of patients with multiple myeloma.
Cytokine 1998;10(12):993-6.
-
1998: Bladé J; Samson D; Reece D; Apperley J; Björkstrand B; Gahrton G; Gertz M; Giralt S; Jagannath S; Vesole D
Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant.
British journal of haematology 1998;102(5):1115-23.
-
1998: Sanz L; López-Guillermo A; Martínez C; Bosch F; Esteve J; Cobo F; Montoto S; Perales M; Bladé J; Cervantes F; Nomdedeu B; Campo E; Montserrat E
Risk of relapse and clinico-pathological features in 103 patients with diffuse large-cell lymphoma in complete response after first-line treatment.
European journal of haematology 1998;61(1):59-64.
-
1998: Bladé J; San Miguel J F; Escudero M L; Fontanillas M; Besalduch J; Gardella S; Arias J; García-Conde J; Carnero M; Marti J M; Rozman C; Estapé J; Montserrat E
Maintenance treatment with interferon alpha-2b in multiple myeloma: a prospective randomized study from PETHEMA (Program for the Study and Treatment of Hematological Malignancies, Spanish Society of Hematology).
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1998;12(7):1144-8.
-
1998: Ocqueteau M; Orfao A; Almeida J; Bladé J; González M; García-Sanz R; López-Berges C; Moro M J; Hernández J; Escribano L; Caballero D; Rozman M; San Miguel J F
Immunophenotypic characterization of plasma cells from monoclonal gammopathy of undetermined significance patients. Implications for the differential diagnosis between MGUS and multiple myeloma.
The American journal of pathology 1998;152(6):1655-65.
-
1998: Alegre A; Díaz-Mediavilla J; San-Miguel J; Martínez R; García Laraña J; Sureda A; Lahuerta J J; Morales D; Bladé J; Caballero D; De la Rubia J; Escudero A; Díez-Martín J L; Hernández-Navarro F; Rifón J; Odriozola J; Brunet S; De la Serna J; Besalduch J; Vidal M J; Solano C; Leon A; Sánchez J J; Martínez-Chamorro C; Fernández-Rañada J M
Autologous peripheral blood stem cell transplantation for multiple myeloma: a report of 259 cases from the Spanish Registry. Spanish Registry for Transplant in MM (Grupo Español de Trasplante Hematopoyético-GETH) and PETHEMA.
Bone marrow transplantation 1998;21(2):133-40.
-
1997: Rozman C; Carreras E; Sierra J; Rovira M; Urbano-Ispizua A; Marín P; Bladé J; Cervantes F; López-Guillermo A; Nomdedeu B; Rozman M; Aguilar J L; Vives-Corrons J L; Mazzara R; Ordinas A; Ribera J M; Feliu E; Castillo R; Grañena A; Montserrat E
[Hemopoietic progenitor cell transplantation: 20 years' experience at the Hematology School "Farreras-Valentí"/Clinical Hospital of Barcelona]
Medicina clínica 1997;108(18):681-6.
-
1996: Björkstrand B B; Ljungman P; Svensson H; Hermans J; Alegre A; Apperley J; Bladé J; Carlson K; Cavo M; Ferrant A; Goldstone A H; de Laurenzi A; Majolino I; Marcus R; Prentice H G; Remes K; Samson D; Sureda A; Verdonck L F; Volin L; Gahrton G
Allogeneic bone marrow transplantation versus autologous stem cell transplantation in multiple myeloma: a retrospective case-matched study from the European Group for Blood and Marrow Transplantation.
Blood 1996;88(12):4711-8.
-
1996: Montserrat E; García-Conde J; Viñolas N; López-Guillermo A; Hernández-Nieto L; Zubizarreta A; Maldonado J; Alcalá A; Faura M V; Llorente A; Bladé J; Fontanillas M; Estapé J
CHOP vs. ProMACE-CytaBOM in the treatment of aggressive non-Hodgkin's lymphomas: long-term results of a multicenter randomized trial.(PETHEMA: Spanish Cooperative Group for the Study of Hematological Malignancies Treatment, Spanish Society of Hematology).
European journal of haematology 1996;57(5):377-83.
-
1996: Bladé J; Muñoz M; Fontanillas M; San Miguel J; Alcalá A; Maldonado J; Besses C; Moro M J; García-Conde J; Rozman C; Montserrat E; Estapé J
Treatment of multiple myeloma in elderly people: long-term results in 178 patients.
Age and ageing 1996;25(5):357-61.
-
1996: Bladé J; San Miguel J F; Fontanillas M; Alcalá A; Maldonado J; García-Conde J; Conde E; Conzález-Brito G; Moro M J; Escudero M L; Trujillo J; Pascual A; Rozman C; Estapé J; Montserrat E
Survival of multiple myeloma patients who are potential candidates for early high-dose therapy intensification/ autotransplantation and who were conventionally treated.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1996;14(7):2167-73.
-
1995: Björkstrand B; Ljungman P; Bird J M; Samson D; Brandt L; Alegre A; Auzanneau G; Bladé J; Brunet S; Carlson K
Autologous stem cell transplantation in multiple myeloma: results of the European Group for Bone Marrow Transplantation.
Stem cells (Dayton, Ohio) 1995;13 Suppl 2():140-6.
-
1995: Gahrton G; Tura S; Ljungman P; Bladé J; Cavo M; De Laurenzi A; Façon T; Gratwohl A; Michallet M; Nikoskelainen J
An update of prognostic factors for allogeneic bone marrow transplantation in multiple myeloma using matched sibling donors. European Group for Blood and Marrow Transplantation.
Stem cells (Dayton, Ohio) 1995;13 Suppl 2():122-5.
-
1995: Gahrton G; Tura S; Ljungman P; Bladé J; Brandt L; Cavo M; Façon T; Gratwohl A; Hagenbeek A; Jacobs P
Prognostic factors in allogeneic bone marrow transplantation for multiple myeloma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1995;13(6):1312-22.
-
1994: Bladé J; Kyle R A
IgD monoclonal gammopathy with long-term follow-up.
British journal of haematology 1994;88(2):395-6.
-
1993: Bladé J; San Miguel J F; Alcalá A; Maldonado J; Sanz M A; García-Conde J; Moro M J; Alonso C; Besalduch J; Zubizarreta A
Alternating combination VCMP/VBAP chemotherapy versus melphalan/prednisone in the treatment of multiple myeloma: a randomized multicentric study of 487 patients.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1993;11(6):1165-71.
-
1992: Bladé J; San Miguel J; Sanz-Sanz M A; Alcalá A; Hernández J M; Martínez M; García-Conde J; Moro J; Ortega F; Fontanillas M
Treatment of melphalan-resistant multiple myeloma with vincristine, BCNU, doxorubicin, and high-dose dexamethasone (VBAD).
European journal of cancer (Oxford, England : 1990) 1992;29A(1):57-60.
-
1990: Bladé J; San Miguel J; Alcalá A; Maldonado J; García-Conde J; Moro M J; Sanz Sanz M A; Alonso C; Zubizarreta A; Besses C
A randomized multicentric study comparing alternating combination chemotherapy (VCMP/VBAP) and melphalan-prednisone in multiple myeloma.
Blut 1990;60(6):319-22.
-
1989: López Guillermo A; Cervantes F; Bladé J; Matutes E; Urbano A; Montserrat E; Rozman C
Central nervous system involvement demonstrated by immunological study in prolymphocytic variant of chronic lymphocytic leukemia.
Acta haematologica 1989;81(2):109-11.
-
1988: Pedro-Botet J; Feliu E; Rozman C; Agustí C; Ribera J M; Bladé J; Martín E; Vives Corrons J L; Mascaró J M
Cutaneous myeloid metaplasia with dysplastic features in idiopathic myelofibrosis.
International journal of dermatology 1988;27(3):179-80.
-
1985: Grañena A; Rozman C; Carreras E; Marín P; Hernández-Prieto M; Olivé M T; Nomdedeu B; Montserrat E; Feliu E; Bladé J
[Bone marrow transplantation in acute leukemia: results in a series of 51 consecutive patients prepared with cyclophosphamide and total body irradiation]
Medicina clínica 1985;85(12):479-85.
-
1985: Rozman C; Grañena A; Marín P; Hernández-Prieto M; Nomdedeu B; Montserrat E; Feliu E; Bladé J; Cervantes F; Vives Corrons J L
[Allogeneic marrow transplantation in severe bone marrow aplasia. Factors determining the outcome in a series of 27 consecutive cases]
Medicina clínica 1985;84(4):129-34.
-
1985: Ribera J M; Bladé J; Brugués R; Vives Corrons J L; Rozman C
[Reversible reticulin myelofibrosis associated with pernicious anemia]
Sangre 1985;30(3):369-71.
-
1984: Montserrat E; Carreras E; Rozman C; Olivé T; Bladé J; Cervantes F; Feliu E; Gardella S; Grañena A; Marín P
[Treatment of Hodgkin's disease with ABVD]
Medicina clínica 1984;83(18):739-41.
-
1984: Gardella S; Cervantes F; Bladé J; Rozman C
[Mediastinal tumor in a patient with acute myeloblastic leukosis]
Medicina clínica 1984;83(9):393-4.
-
1984: Bladé J; Rozman C; Montserrat E; Grañena A; Brugués R; Cervantes F; Feliu E; Marín P; Nomdedeu B; Vives-Corrons J L
[Multiple myeloma: description of a series of 170 cases]
Medicina clínica 1984;82(7):287-94.
-
1984: Ribera J M; Bladé J; Ercilla G; Feliú E; Rozman C
[Idiopathic thrombocytopenic purpura following recovery from a benzol-induced bone marrow aplasia]
Sangre 1984;29(2):224-5.
-
1984: Gardella S; Cervantes F; Bladé J; Sánchez Bisonó J; Grañena A; Rozman C
Acute myeloblastic leukaemia presenting with superior vena cava syndrome due to mediastinal mass.
Acta haematologica 1984;71(3):174-7.
-
1984: Cervantes F; Rozman C; Ballesta F; Bladé J; Feliú E; Grañena A; Marin P; Montserrat E; Nomdedeu B; Vives Corrons J L
[Clinico-biological expression of chronic granulocytic leukemia in the diagnostic phase and its prognostic significance]
Sangre 1984;29(4-B):504-20.
-
1983: Ribera J M; Bladé J; Cervantes F; Feliu E; Sierra J; Brugués R; Rozman C
[Osteolytic lesions in idiopathic myelofibrosis: presentation of 2 cases]
Medicina clínica 1983;81(19):861-4.
-
1983: Bladé J; Feliú E; Rozman C; Estapé J; Millá A; Montserrat E
Cross-resistance to alkylating agents in multiple myeloma.
Cancer 1983;52(5):786-9.
-
1983: Cervantes F; Rozman C; Ballesta F; Bladé J; Brugués R; Feliu E; Grañena A; Marín P; Montserrat E; Nomdedeu B; Salguero R
[Chronic myelogenous leukaemia. Report of a series of 207 patients]
Sangre 1983;28(2):140-50.
-
1982: Gardella S; Cervantes F; Bladé J; Brugués R; Rozman C
[Acute myeloproliferative syndrome after alkylating agent treatment in a case of multiple myeloma]
Medicina clínica 1982;79(4):185-8.
Sign-in to see more
